In the Phase 1 portion of the trial, both dose-escalation and duration-extension cohorts will be utilized to evaluate IMG-7289 as a single agent; additionally, an IMG-7289 plus ATRA combination treatment regimen will be investigated. Pending evaluations of safety and clinical benefit, patients will be eligible to enroll in a Phase 2 expansion arm to evaluate longer-term anti-tumor activity. The trial targets enrollment of approximately 30 patients and is being conducted at six sites.
IMG-7289 is a small molecule developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem cells, particularly malignant bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents. IMG-7289 is an investigational agent currently being evaluated in an ongoing clinical trial (ClinicalTrials.gov Identifier: NCT02842827).
About Imago BioSciences
Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. These include a range of hematologic malignancies including AML, MDS and the myeloproliferative neoplasms. The company is based in California.
Please see the website at www.imagobio.com for additional information.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imago-biosciences-enrolls-first-patient-in-phase-12-study-of-img-7289-in-acute-myeloid-leukemia-and-myelodysplastic-syndrome-300359030.html
SOURCE Imago BioSciences